LBIOME
LIVE

Serial Number

79320342

Owner

DSM - Firmenich Houdan SAS

Attorney

Duane M. Byers

Filing Date

May 20, 2021

Add to watchlist:

No watchlists yet
View on USPTO

LBIOME Trademark

Serial Number: 79320342 • Registration: 7033011

LBIOME is a trademark filed by DSM - Firmenich Houdan SAS on May 20, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

DSM - Firmenich Houdan SAS (5 trademarks)

Route de Bû Lieu-dit "La Prévoté"

Entity Type: 98

Adare Pharmaceuticals SAS (3 trademarks)

Route de Bû Lieu-dit "La Prévoté"

Entity Type: 99

Trademark Details

Filing Date

May 20, 2021

Registration Date

April 25, 2023

Published for Opposition

February 7, 2023

Goods & Services

Customized manufacture, for third parties, of pharmaceuticals, nutritional and food supplements featuring live or inactivated microorganisms; manufacture of ingredients comprising inactivated, heat-treated Lactobacillus strains and their fermentation medium, namely, Lactobacillus LB, consisting of a combination of Lactobacillus delbreuckii and Lactobacillus fermentum as ingredients; custom manufacture, for third parties, of pharmaceutical and nutritional supplemental ingredients, namely, enriched culture medium and heat-treated microorganisms; manufacture of pharmaceutical ingredients, namely, heat-treated micro-organisms, for preparation of tablets, capsules, powders, injectable products, suspensions, liquids, for medical and veterinary use

Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations for the treatment and prevention of gastrointestinal infections, dysbiosis, diarrhea, irritable bowel syndrome, inflammatory bowel disease, abdominal pain, colitis, vaginal infections, obesity, allergy, stress, anxiety, autisms, depression, mood disturbance, sociability disturbance, sleep disturbance, psychological disturbance, obsessive-compulsive disorders, addiction, fibromyalgia, cancer, post-traumatic stress, mucosal and systemic inflammation, necrotizing enterocolitis, enteritis, skin inflammation, and skin infections, and veterinary pharmaceutical preparations for the treatment and prevention of gastrointestinal infections, dysbiosis, diarrhea, irritable bowel syndrome, inflammatory bowel disease, abdominal pain, colitis, vaginal infections, obesity, allergy, stress, anxiety, depression, mood disturbance, sociability disturbance, sleep disturbance, fibromyalgia, cancer, post-traumatic stress, mucosal and systemic inflammation, enteritis, skin inflammation, and skin infections; dietetic foods adapted for medical and veterinary use; bacterial preparations for medical and veterinary use; probiotic bacteria preparations for medical use; foodstuffs and nutritional and food supplements featuring live or inactivated microorganisms, namely, nutritional supplements, enzyme food supplements, dietary food supplements, food supplements for humans and animals; ingredients based on inactive bacteria preparations and heattreated and heat-stabilized bacteria preparations, namely, Lactobacillus strains in combination with fermentation medium featured as a component ingredient of pharmaceutical and veterinary preparations and nutritional and dietary supplements; ingredients based on combinations of inactivated and heat-treated Lactobacillus delbrueckii and Lactobacillus fermentum and fermentation medium sold as a component ingredient of pharmaceutical and veterinary preparations and nutritional and dietary supplements; additives in the nature of dietary supplements for humans or for animals; ferments for medical or veterinary use with postbiotic or probiotic effects

Medical and pharmaceutical research and development in the field of microbiology, immunology, mucosal immunology, gastroenterology, internal medicine, psychology, psychiatry, neurology, behavioral science, inflammatory disorders, sarcopenia, health by nutrition, dermatitis, allergies, infectiology, endocrinology, postbiotics; scientific research and development; bacteriological scientific research and consultation; provision of information and data relating to medical and veterinary research and development; provision of scientific and technological information in the field of microbiology, immunology, mucosal immunology, gastroenterology, internal medicine, psychology, psychiatry, neurology, behavioral science, inflammatory disorders, sarcopenia, health by nutrition, dermatitis, allergies, infectiology, endocrinology, postbiotics; design and development of pharmaceuticals, nutritional supplements and dietetic supplements comprising living and inactivated microorganisms; research and development of formulations, namely, pharmaceuticals, nutritional supplements, and dietary supplements for the administration of heat-treated Lactobacillus strains combined with their fermentation medium, namely, Lactobacillus LB, consisting of a combination of Lactobacillus delbreuckii and Lactobacillus fermentum as ingredients; research and development of pharmaceutical ingredients based on enriched culture medium and heat-treated bacteria, namely, Lactobacillus strains; research and development of formulations, namely, pharmaceutials, nutritional supplements, and dietetic supplements, based on enriched culture medium and heat-treated micro-organisms; technological consultation in the field of bacteria-based ingredients and in the field of postbiotics

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 15, 2024 NREP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jul 19, 2024 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Nov 4, 2023 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 6, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 6, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 6, 2023 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 20, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 2, 2023 FICS
FINAL DISPOSITION PROCESSED
Aug 2, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 25, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 25, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 25, 2023 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 14, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 22, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 22, 2023 OPNR
CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Feb 7, 2023 CHPB
NOTIFICATION PROCESSED BY IB
Feb 7, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 7, 2023 NPUB
PUBLISHED FOR OPPOSITION
Feb 7, 2023 PUBO
ASSIGNED TO PETITION STAFF
Feb 1, 2023 APET
POST PUBLICATION AMENDMENT RECEIVED
Feb 1, 2023 PPAR
ASSIGNED TO PETITION STAFF
Jan 30, 2023 APET
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 18, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 18, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 18, 2023 NONP
TEAS POST PUBLICATION AMENDMENT RECEIVED
Jan 17, 2023 EPPA
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 4, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 31, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 30, 2022 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Dec 30, 2022 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 3, 2022 GNFN
FINAL REFUSAL E-MAILED
Sep 3, 2022 GNFR
FINAL REFUSAL WRITTEN
Sep 3, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 5, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 5, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 5, 2022 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 26, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 26, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 26, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 26, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 26, 2022 COAR
REFUSAL PROCESSED BY IB
Mar 27, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 9, 2022 RFCS
REFUSAL PROCESSED BY MPU
Mar 9, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 11, 2022 RFCR
NON-FINAL ACTION WRITTEN
Feb 10, 2022 CNRT
ASSIGNED TO EXAMINER
Feb 1, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 28, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 24, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 16, 2021 REPR